US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% META $728.08 ▲+0.00% NVDA $233.95 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00% JNJ $256.03 ▲+0.00% SPCX $158.96 ▲+0.00%
FinancialContent

Articles published by Alpha Cognition, Inc.

News headline image
Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer’s Disease
From Alpha Cognition, Inc.
Via Business Wire
Tickers ACOG
News headline image
Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences
From Alpha Cognition, Inc.
Via Business Wire
Tickers ACOG
News headline image
Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution
From Alpha Cognition, Inc.
Via Business Wire
Tickers ACOG
News headline image
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China
From Alpha Cognition, Inc.
Via Business Wire
Tickers ACOG